Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression On Novel Hormonal Therapies Plus Avelumab

CONCLUSION: In conclusion, the addition of avelumab to NHT did not demonstrate clinical activity in Black men with new mCRPC. The unexpected short interval between PSA and radiographic and/or clinical progression observed in this study has potential clinical implications.ClinicalTrials.gov Identifier: NCT03770455 (IND number 139559).PMID:36210487 | DOI:10.1093/oncolo/oyac203

Source: The Oncologist - October 9, 2022 Category: Cancer & Oncology Authors: Charlotte Hawkins Pedro C Barata Patrick Cotogno Gaynelle Davis Ellen Jaeger Elisa Ledet Patrick Miller Brian Lewis Oliver Sartor Jodi Layton Source Type: research